Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
The British Journal of Ophthalmology
|
August 25, 2017
Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data
Aaron Y Lee, Thomas Butt, Emily Chew, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
December 8, 2021
Evaluating discrete choice experiment willingness to pay [DCE-WTP] analysis and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare childhood disease [CLN2]
Domenico Moro, Michael Schlander, Harry Telser, et al.
Plos One
|
May 22, 2024
Exploring concurrent validity of the CLN2 Clinical Rating Scale: Comparison to PedsQL using cerliponase alfa clinical trial data
Nicola Specchio, Paul Gissen, Emily de Los Reyes, et al.
Orphanet Journal of Rare Diseases
|
June 13, 2022
Literature review and expert opinion on the impact of achondroplasia on medical complications and health-related quality of life and expectations for long-term impact of vosoritide: a modified Delphi study
Ravi Savarirayan, Wagner Baratela, Thomas Butt, et al.
The British Journal of Ophthalmology
|
March 31, 2022
Disease-specific assessment of Vision Impairment in Low Luminance in age-related macular degeneration - a MACUSTAR study report
Jan Henrik Terheyden, Susanne G Pondorfer, Charlotte Behning, et al.
Orphanet Journal of Rare Diseases
|
May 13, 2021
Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2)
Paul Gissen, Nicola Specchio, Andrew Olaye, et al.
Eclinicalmedicine
|
May 17, 2021
Global economic productivity losses from vision impairment and blindness
Ana Patricia Marques, Jacqueline Ramke, John Cairns, et al.
Eclinicalmedicine
|
March 28, 2022
The economics of vision impairment and its leading causes: A systematic review
Ana Patricia Marques, Jacqueline Ramke, John Cairns, et al.
BMJ Open
|
September 8, 2020
Estimating the global cost of vision impairment and its major causes: protocol for a systematic review
Ana Patricia Marques, Jacqueline Ramke, John Cairns, et al.
The British Journal of Ophthalmology
|
February 15, 2015
UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12
Aaron Y Lee, Cecilia S Lee, Thomas Butt, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
The British Journal of Ophthalmology
|
August 25, 2017
Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data
Aaron Y Lee, Thomas Butt, Emily Chew, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
December 8, 2021
Evaluating discrete choice experiment willingness to pay [DCE-WTP] analysis and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare childhood disease [CLN2]
Domenico Moro, Michael Schlander, Harry Telser, et al.
Plos One
|
May 22, 2024
Exploring concurrent validity of the CLN2 Clinical Rating Scale: Comparison to PedsQL using cerliponase alfa clinical trial data
Nicola Specchio, Paul Gissen, Emily de Los Reyes, et al.
Orphanet Journal of Rare Diseases
|
June 13, 2022
Literature review and expert opinion on the impact of achondroplasia on medical complications and health-related quality of life and expectations for long-term impact of vosoritide: a modified Delphi study
Ravi Savarirayan, Wagner Baratela, Thomas Butt, et al.
The British Journal of Ophthalmology
|
March 31, 2022
Disease-specific assessment of Vision Impairment in Low Luminance in age-related macular degeneration - a MACUSTAR study report
Jan Henrik Terheyden, Susanne G Pondorfer, Charlotte Behning, et al.
Orphanet Journal of Rare Diseases
|
May 13, 2021
Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2)
Paul Gissen, Nicola Specchio, Andrew Olaye, et al.
Eclinicalmedicine
|
May 17, 2021
Global economic productivity losses from vision impairment and blindness
Ana Patricia Marques, Jacqueline Ramke, John Cairns, et al.
Eclinicalmedicine
|
March 28, 2022
The economics of vision impairment and its leading causes: A systematic review
Ana Patricia Marques, Jacqueline Ramke, John Cairns, et al.
BMJ Open
|
September 8, 2020
Estimating the global cost of vision impairment and its major causes: protocol for a systematic review
Ana Patricia Marques, Jacqueline Ramke, John Cairns, et al.
The British Journal of Ophthalmology
|
February 15, 2015
UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12
Aaron Y Lee, Cecilia S Lee, Thomas Butt, et al.
Page
of 4